Introduction
Chronic lymphocytic leukemia (CLL), while incurable with conventional chemotherapy, may be susceptible to T cellmediated approaches. 1 Consistent with this, we found that autologous tumor vaccines increased CLL-reactive T cell activity, and caused partial responses, in some patients. 1 However, the absence of complete remissions suggested a need for additional measures.
Cytotoxic T cells (CTLs), which are required to clear cancer cells, evolved likely to deal with viral infections. 2 Along with antigen-reactive T cells, successful antiviral and antitumor responses require that the target cells be immunogenic. Immunogenicity is a complex phenotype involving the production of costimulatory molecules, cytokines, and chemokines that promote CTL proliferation and function. Unfortunately, tumor cells have inherently weak immunogenicity and often make immunosuppressive factors. 3 Methods to enhance tumor cell immunogenicity might then improve the efficacy of cancer vaccines, in general, and CLL vaccines, in particular.
Signaling events in virus-infected target cells during protective CTL responses provide a guide to develop strategies to enhance CLL immunogenicity. 2 Viruses provide antigenic targets for CTLs and also activate the adaptive immune system through toll-like receptors (TLRs). 4 TLRs recognize pathogen-associated molecular patterns (PAMPs) and activate transcription factors that control the expression of costimulatory molecules (such as the B7-family members, CD80 and CD86, the adhesion molecule, CD54, and CD83), and type 1 immunity-promoting cytokines such as Interferon (IFN)a and IL12. TLR1, 2, 4, 5, and 9 recognize mainly bacterial PAMPs 4 and CpG oligonucleotides (which activate TLR9) are known to affect immunological parameters of CLL cells. 5 TLR3 recognizes double-stranded viral RNA 4 while TLR7 (expressed mainly by B cells and monocytes) recognizes single-stranded viral RNA in endosomes and activates NF-kB and p38 mitogen activated protein kinase (MAPK) signaling pathways through a phospho-relay system involving MyD88, interleukin-1 receptor associated kinase (IRAK)1, IRAK4, and TNF receptor associated factor (TRAF) 6. 4 TLR7 is of clinical interest because it can be activated pharmacologically by imidazoquinolines 6 and guanosine analogs. 7 The experiments in this paper were designed to study the effect of TLR7 agonists on immunogenic properties of CLL cells.
Materials and methods

Cell samples
Blood was taken from consenting CLL patients (with a persistent clonal expansion of CD19 þ CD5 þ IgM lo lymphocytes 8 ) who were untreated for more than 3 months. Normal B cells were from healthy volunteers and phlebotomized hemochromatosis patients. Protocols were approved by the Local Review Board. Patient characteristics are described in Table 1 .
Antibodies and reagents
Fluorescent CD38, CD80, CD86, CD54, CD83, CD5, CD19, CD40, CD95, MHC, and tumor necrosis factor (TNF) antibodies were from Pharmingen (San Francisco, CA). Lipopolysaccharide (LPS), Loxoribine, phorbol dibutyrate (PDB), phytohemaggluti-nin (PHA), chloroquine, and 2-mercaptoethanol (2-ME) were from Sigma Chemical Co. (St Louis, MO). Dexamethasone (Pharmascience Inc., Montreal, Quebec), IL2 (Chiron Corp., San Francisco, CA), IFNa2b (Schering, Pointe-Claire, Quebec) and Remicade (Centocor, Horsham, PA) were from the hospital pharmacy. Poly (I:C) was from Amersham Pharmacia Biotech Inc. (Piscataway, NJ). AG490, AG126, SB203580, and Bafilomycin A1 were from Calbiochem (San Diego, CA). S28690 9 was from 3M Pharmaceuticals (St Paul, MN). IL6 and IL10 antibodies were from R&D Systems, Inc. (Minneapolis, MN). 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) was from Molecular Probes (Eugene, OR). Staphylococcal enterotoxin A (SEA) was from Toxin Technology Inc. (Madison, WI). The TACE inhibitor, TAPI, 10, 11 was from Peptides International (Louisville, KY).
Cell purification CLL, normal B, and T cells were isolated as described previously. 12 Activation of CLL cells CLL cells (1.5 Â 10 6 /ml) were cultured in serum-free AIM-V medium (GibcoBRL, Grand Island, NY) plus 2-ME (5 Â 10
in six-well plates (Becton-Dickinson Labware, Franklin Lake, NJ) for 3-4 days. S28690 and PDB were used at 1 mg/ml and 100 ng/ml, respectively. IL10 and IL6 antibodies were used at 15 mg/ml.
T-cell proliferation assays
Mixed lymphocyte responses (MLRs) were performed as described.
12 PHA (10 mg/ml) was added to some cultures as a positive control for proliferation.
SEA-directed cytotoxicity assay Effectors. Lymphokine activated killer (LAK) cells were made from normal peripheral blood mononuclear cells (PBMCs) cultured in AIM-V with IL2 (500 U/ml) for 7-10 days and fed every 3 days. SEA-reactive T cells were made from PBMCs stimulated with SEA (1 ng/ml) in AIM-V plus 10% FCS for 10-14 days. Effectors were collected by density gradient centrifugation and suspended in AIM-V.
Targets. CLL cells were suspended at 1 Â 10 7 /ml in phosphate-buffered saline (PBS) plus 5% FCS and then pelleted and incubated with 100 ml of CFSE (50 mM in PBS) for 5 min at room temperature in the dark before being washed and resuspended in AIM-V.
Assay. Effectors (at 1 and 3 Â 10 6 /ml) and targets (at 1 Â 10 6 /ml) were mixed (1:1) in a final volume of 200 ml in 5 ml polystyrene tubes (BD Biosciences, Bedford, MA) and cultured for 4 h at 371C. SEA (1 ng/ml) was added to some tubes to activate effector cells and bind them to targets. 13 The samples were then washed twice and 7-amino actinomycin D (7-AAD) and Annexin V-PE were added, according to the manufacturer's instructions (BDPharmingen).
Immunophenotyping
Flow cytometric analysis was performed as described previously.
14 For cellular cytotoxicity, gates were set on CFSEstained CLL cells using an FL1-histogram. The percentages of target cells that bound Annexin V-PE and/or 7AAD were determined by further gating in an FL2/FL3 dot-plot (see Figure 4d for an example).
Immunoblotting
Immunoblotting was performed as described 14 on resting CLL cells (with IRAK1, IRAK4, MyD88 (eBioscience, San Diego, CA) and TRAF6 (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies) and activated CLL cells (with IkB, phospho-IkB (Ser 32) (New England BioLabs Inc., Beverly, MA), signal transducer and activator of transcription (STAT)3, phospho-STAT3 (Y705), and b-actin antibodies (Cell Signaling, Beverly, MA). 
Real-time PCR amplification
Total RNA and cDNA were made as described before.
12 TLR7 and HPRT transcripts were amplified with the primers: TLR7 GCTCTTCAGTCTGA-3 0 ). PCR was performed on a DNA engine Opticont System (MJ Research Inc., Waltham, MA) using SYBR Green I as a double-strand DNA-specific binding dye. Reactions were cycled 40 times after initial denaturation (951C, 15 min) using the parameters: denaturation at 951C for 15 s, annealing at 541C (TLR7) and 521C (HPRT) for 20 s, and extension at 721C for 20 s. Fluorescent data were acquired during each extension phase. Melting curve analyses of amplification products were performed by cooling the samples to 41C and then increasing the temperature to 951C at 0.21C/s. Fast loss of fluorescence is observed uniquely at the denaturing/melting temperature of the amplified DNA fragment. Standard curves were generated with serial 10-fold dilutions of cDNAs obtained with the same primers used for real-time PCR.
Cytokine measurement
Cytokines in supernatants were measured with the respective ELISA kits (Pierce Biotechnology Inc., Rockford, IL), according to the manufacturer's instructions.
Statistical analysis
The Student's t-test and paired t-tests were used to determine P-values. Best-fit lines were determined by least-squares regression.
Results
Costimulatory molecule expression on TLR7-activated CLL cells
A number of immunogenic molecules were measured on CLL cells treated with different TLR agonists. CD54, CD80, CD86, and CD83 levels increased on all CLL patient samples (regardless of clinical stage) in response to the imidazoquinoline, S28690. CD40, Class I and Class II MHC molecules -already expressed highly on resting cellsincreased further upon stimulation with S28690 ( Figure 1a and Supplementary Figure 1) . Loxoribine (also a TLR7 agonist 7 ) had similar effects as S28690, while TLR3 and -4 agonists (poly (I:C) and LPS, respectively) and the antiviral cytokine, IFNa2b, did not change costimulatory molecule expression by CLL cells significantly (Figure 1b) .
While all patient samples responded to S28690, heterogeneity in responsiveness was apparent. For example, increases in CD80 were found to be proportional to base-line expression of CD38, a surface molecule associated with aggressivity of CLL 8 ( Figure 1c) . To address the issue of variable responsiveness to S28690, components of the TLR7-signaling pathway were measured.
4 TLR7 protein could not be detected by immunoblotting with commercially available antibodies. However, all patient samples expressed TLR7 mRNA. Absolute levels of TLR7 message varied somewhat but no obvious correlation with responsiveness to S28690 (determined by changes in costimulatory molecule expression) was noted. Interestingly, TLR7 mRNA expression was several-fold lower in CLL cells compared to normal PBMCs (Figure 1d ). Other components of the TLR7-signaling pathway (MyD88, IRAK1, IRAK4, and TRAF6) were expressed by all CLL samples with some variation and without obvious relationship to S28690-mediated changes in costimulatory molecule expression (Figure 1e ).
Mechanism of costimulatory molecule changes
Treatment with S28690 led to the rapid activation of NFkB (determined by phosphorylation of the inhibitor protein, IkB, which releases NFkB to engage in gene transcription 4 ) (Figure 2a ) and costimulatory molecule expression was inhibited in an additive fashion by dexamethasone (an inhibitor of NFkBmediated gene transcription 15 ) and SB203580 (a specific p38 kinase inhibitor 16 ) (exemplified in Figure 2b and summarized in Figure 2c ). The effects of S28690 on NFkB-mediated gene transcription were also inhibited by AG126 (an IRAK1 inhibitor 17 ) and the endosomal inhibitors, chloroquine, and bafilomycin 7 ( Supplementary Figure 2) , consistent with signaling through TLR7.
Indirect STAT3 activation by S28690
The immunogenic phenotype required for successful antitumor T-cell responses is also affected by other signaling pathways. In particular, the STAT family member, STAT3, is considered a negative regulator of immunogenicity.
18 STAT3 was activated in S28690-treated CLL cells (indicated by the appearance of tyrosine-phosphorylated forms (Figure 2d) ). However, phospho-STAT3 did not appear for several hours, and could be blocked by IL6 and IL10 antibodies (Figure 2d , upper panels), suggesting it resulted from autocrine production of these cytokines, rather than direct signaling through TLR7.
Phorbol esters also block IL10 and IL6-mediated STAT3 activation. 19 Consistent with this, phospho-STAT3 levels were decreased in S28690-activated CLL cells treated simultaneously with PDB (Figure 2d , middle panels). Similar results were observed with another inhibitor of STAT3 activation, AG490 18 ( Figure 2d , lower panels).
Cytokine and chemokine production by S28690-treated CLL cells
The prevention of STAT3 phosphorylation by anti-IL6 and -IL10 suggested that cytokines stimulated by S28960 might affect the Given their ability to inhibit STAT3 activation, we hypothesized that concomitant treatment with phorbol esters would enhance the immunogenic properties of S28690-treated CLL cells. Consistent with this, TNFa levels were about 10-fold higher (and a trend towards increased IL6, IL8, and IL1 production was noted) in the presence of both S28690 and PDB (Figure 3) .
Effect of phorbol esters on costimulatory molecule expression by S28690-activated CLL cells
Costimulatory molecules were also measured on CLL cells treated concomitantly with PDB. PDB, alone, caused CD83 expression by B90% of CLL cells and increased percentages of CD80 þ and CD86 þ cells (Figure 4b) . Remarkably, the combination of S28690 and PDB caused essentially all hi cell surface phenotype (Figure 4a, b) , which is characteristic of potent antigen presenting cells (APCs), such as dendritic cells (DCs). 12 The effects on CD80 and CD54 were particularly strong.
Effect of S28690 on costimulatory function and sensitivity to cytotoxic effectors
The desired outcome of modulating immunogenic properties of tumor cells is to increase their ability to support T-cell activity and sensitivity to killing by CTLs. 3 Despite increased costimulatory molecule and cytokine expression, S28690-treated CLL cells did not cause strong proliferation of T cells in MLRs. Concomitant treatment with phorbol esters caused S28690-treaed CLL cells to stimulate T cell proliferation more strongly, but not to levels reached with the T-cell mitogen, PHA (Figure 4c) .
A flow cytometric assay was developed to evaluate the sensitivity of CLL cells (treated with S28690 for 2 days) to CTLs. CLL targets were labeled with CFSE and then incubated with effector cells. Annexin-V (to label apoptotic cells) and 7-AAD (to identify necrotic cells) were then added and the percentages of dead and dying CLL target cells determined by gating on FITC þ cells. 21 CLL cells were relatively resistant to killing by LAK cells, despite S28690 (not shown). Using SEA-reactive T-cell lines (shown previously to kill CLL cells 13 ) as effectors, S28690-activated CLL cells were found to be significantly more susceptible to killing (Figure 4d ).
Effect of S28690 on normal B cells
Normal B cells were studied to determine if immunomodulatory effects of S28690 were specific to CLL cells ( Figure 5 ). S28690 caused qualitatively similar changes in CD80, CD86, CD54, and CD83 expression on normal B cells (Figure 5a ). The major difference was that the percentage of cells that expressed CD80, and the mean fluorescence intensity (MFI) of expression, (63.774.6% and 4074.7 (n ¼ 10), respectively) after treatment with PDB and S28690 ( Figure 5a ) were less than CLL cells treated similarly (97.570.6% of cells with MFI of 117.3742.8 (n ¼ 15)) (Po0.01 for both parameters). As with CLL cells (Figure 4c ), the ability of normal B cells to stimulate T-cell proliferation in allogeneic MLRs was increased only marginally by S28690 but increased further with concomitant PDB treatment (Figure 5b) .
Potential T-cell-mediated destruction of normal B cells that have been made more immunogenic by S28690 in vivo is an important clinical consideration. To model this situation, purified autologous T cells (which do not express TLR7 22 ) were cultured with B cells in the presence of S28690 and/or PDB. The absolute number of B cells remaining at the end of the culture period was then calculated from the percentage of CD19 þ cells and the total viable cell number (Figure 5c ). S26890 generally increased B cell numbers at the end of the culture period. The effect of PDB was more variable, but resulted generally in more B cell clearance.
The spectrum of cytokines made by normal B cells in response to S28690 was similar to CLL cells. However, the magnitude of IL6, IL8 IL1b, and IFNg production was higher and stimulation with both S28690 and PDB resulted in much greater production of IL8 and IP10 (compare Figure 5d , top and bottom panels).
Discussion
The results in this paper show that TLR7 regulates a number of immunogenic properties of CLL cells. S28690 increased costimulatory molecule expression by CLL cells (Figure 1 ) through TLR7-signaling pathways (Figure 2, Supplementary  Figure 2 ). Activation with both S28690 and PDB, caused CLL cells to acquire uniformly a cell surface phenotype characterized by high CD80, CD86, CD54, and CD83 expression ( Figure  4a , b) and to increase proinflammatory cytokine production (especially TNFa) (Figure 3 ), while decreasing phosphorylated STAT3 levels (Figure 2d ). These features are shared by mature DCs, which are considered the most potent APCs. 12 Despite near uniformity in response to S28690 and phorbol esters (Figure 4b ), heterogeneity in costimulatory molecule expression and cytokine production was observed when CLL cells were treated with S28690 as a single agent (Figure 1 ). This heterogeneity was related to CD38 expression ( Figure 1 ) and perhaps to variations in expression of TLR7 (Figure 1d ) and its associated signaling molecules (such as MyD88 and IRAK1 (Figure 1e) ). Further studies are required to explain the variation in TLR7-responsiveness, which may reflect the underlying cytogenetic aberrations that drive CLL progression 8 or possibly previous activation of CLL cells in vivo by endogenous TLR ligands or cytokines whose receptors share components of the TLR7-signaling pathway. 23 Previously, we found that autologous vaccines (made from oxidized tumor cells) caused partial clinical responses in some CLL patients. 1 The observation that CLL cells invariably acquired properties of DCs when treated with both S28690 and a protein kinase C (PKC) agonist could be exploited to make more potent patient-specific vaccines in vitro. CLL cells treated with S28690 alone did not stimulate strongly T-cell proliferation (Figure 4c ) but were killed more easily by superantigenactivated T cells in a redirected cytotoxicity assay (Figure 4e ). While this assay does not mimic a putative in vivo situation with fidelity, it may suggest that S28690-activated CLL cells may be more susceptible to killing by tumor-reactive T cells. The mechanism of enhanced killing by CTLs is not clear. It does not appear to be mediated through TNFa receptors (as TNFa antibodies did not block killing (not shown)) but may be related to enhanced expression of FAS by S28690-activated CLL cells (Figure 1a) . Another TLR7-agonist (Loxoribine) increased the sensitivity of CLL cells to chemotherapeutic agents. 24 We suggest that the ability of TLR7-agonists to promote killing of CLL cells may be exploited in treatments for CLL.
Consistent with this, we found that topical administration of an imidazoquinoline (Imiquimod) resulted in clearance of leukemic skin infiltrates in a CLL patient. 9 Although little impact on systemic disease was observed with this route of administration, the strong local effects (and the results of this paper) justify a clinical trial to investigate the effects of intravenous administration of imidazoquinolines to achieve higher concentrations. Such a trial would establish the toxicity in CLL patients (including the potential effects on normal B cells ( Figure 5) ) and may reveal that TLR7-agonists have activity as single agents (perhaps by sensitizing CLL cells to tumor-reactive T cells found in some patients 14 ). Alternatively, infusions of imidazoquinolines (to sensitize CLL cells to CTLs) following cancer vaccines or adoptive T-cell transfer (to increase CLL-reactive T cell numbers and activity) may be an effective immunotherapeutic strategy for CLL.
